SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 225.59 |
| Enterprise Value ($M) | 38.05 |
| Book Value ($M) | 552.95 |
| Book Value / Share | 11.96 |
| Price / Book | 0.41 |
| NCAV ($M) | 459.68 |
| NCAV / Share | 9.94 |
| Price / NCAV | 0.49 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.42 |
| Return on Equity (ROE) | -0.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.33 |
| Current Ratio | 17.33 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 510.76 |
| Assets | 604.03 |
| Liabilities | 51.08 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 10.70 | 1.98 | |
| 13G/A | Ra Capital Management, L.p. | 11.00 | -2.00 | |
| 13G/A | Deep Track Capital, LP | 7.88 | 79.33 | |
| 13G/A | Janus Henderson Group Plc | 6.00 | 1.42 | |
| 13G/A | Viking Global Investors Lp | 0.00 | -100.00 | |
| 13G/A | Biotechnology Value Fund L P | 14.20 | 84.22 | |
| 13G/A | Vanguard Group Inc | 5.32 | 0.00 | |
| 13G | Goldman Sachs Group Inc | 6.90 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 8.90 | 52.38 | |
| 13G/A | Kirn David | 4.70 | 0.52 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 99,452 | 571,044 | 17.42 | |
| 46,340 | 572,024 | 8.10 | |
| 171,720 | 1,098,202 | 15.64 | |
| 137,416 | 623,781 | 22.03 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ERAS – Erasca, Inc. | EWTX – Edgewise Therapeutics, Inc. |
| EXEL – Exelixis, Inc. | FGEN – FibroGen, Inc. |
| GBIO – Generation Bio Co. |
Financial data and stock pages provided by
Fintel.io